Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERNA NASDAQ:IMA NASDAQ:MDCX NASDAQ:PLUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERNAErnexa Therapeutics$1.25+5.5%$1.63$1.17▼$22.35$9.55M5.66284,475 shs84,917 shsIMAImageneBio$8.52-4.9%$14.18$7.95▼$23.28$34.25M0.517,759 shs93,380 shsMDCXMedicus Pharma$2.61+5.2%$2.43$1.79▼$8.94$46.50MN/A237,204 shs377,054 shsPLURPluri$4.99+1.7%$5.07$3.33▼$7.13$39.23M0.6919,780 shs4,687 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERNAErnexa Therapeutics-8.53%-4.84%-25.55%-53.36%-94.76%IMAImageneBio-1.97%-3.55%-36.90%-45.10%-55.82%MDCXMedicus Pharma+2.90%+18.66%+26.53%-3.50%+247,999,900.00%PLURPluri-6.38%-2.22%-6.94%+9.08%-13.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERNAErnexa Therapeutics$1.25+5.5%$1.63$1.17▼$22.35$9.55M5.66284,475 shs84,917 shsIMAImageneBio$8.52-4.9%$14.18$7.95▼$23.28$34.25M0.517,759 shs93,380 shsMDCXMedicus Pharma$2.61+5.2%$2.43$1.79▼$8.94$46.50MN/A237,204 shs377,054 shsPLURPluri$4.99+1.7%$5.07$3.33▼$7.13$39.23M0.6919,780 shs4,687 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERNAErnexa Therapeutics-8.53%-4.84%-25.55%-53.36%-94.76%IMAImageneBio-1.97%-3.55%-36.90%-45.10%-55.82%MDCXMedicus Pharma+2.90%+18.66%+26.53%-3.50%+247,999,900.00%PLURPluri-6.38%-2.22%-6.94%+9.08%-13.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERNAErnexa Therapeutics 0.00N/AN/AN/AIMAImageneBio 2.50Moderate Buy$35.50316.67% UpsideMDCXMedicus Pharma 3.50Strong Buy$23.50800.38% UpsidePLURPluri 3.00Buy$12.00140.72% UpsideCurrent Analyst Ratings BreakdownLatest ERNA, IMA, MDCX, and PLUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/22/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.008/13/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.007/25/2025IMAImageneBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$25.00 ➝ $23.007/9/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.007/1/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.006/23/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERNAErnexa Therapeutics$580K16.46N/AN/A$0.50 per share2.49IMAImageneBio$9.16M3.74N/AN/A$31.33 per share0.27MDCXMedicus PharmaN/AN/AN/AN/A$0.29 per shareN/APLURPluri$330K118.88N/AN/A$1.00 per share4.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/A-7,652.75%N/A-682.08%11/10/2025 (Estimated)IMAImageneBio-$49.23M-$7.68N/AN/AN/AN/A-23.94%-21.62%N/AMDCXMedicus Pharma-$11.16M-$1.34N/AN/AN/AN/A-549.30%-228.06%11/28/2025 (Estimated)PLURPluri-$20.89M-$5.53N/A∞N/A-2,563.29%-4,191.91%-85.40%9/17/2025 (Estimated)Latest ERNA, IMA, MDCX, and PLUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/17/2025N/APLURPluri-$0.73N/AN/AN/A$0.40 millionN/A8/13/2025Q2 2025ERNAErnexa TherapeuticsN/A-$0.61N/A-$0.61N/AN/A8/11/2025Q2 2025MDCXMedicus Pharma-$0.39-$0.43-$0.04-$0.43N/AN/A7/24/2025Q2 2025IMAImageneBio-$0.14-$0.06+$0.08-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERNAErnexa TherapeuticsN/AN/AN/AN/AN/AIMAImageneBioN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERNAErnexa TherapeuticsN/A1.811.81IMAImageneBioN/A13.5213.52MDCXMedicus PharmaN/A1.291.29PLURPluri51.654.814.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERNAErnexa Therapeutics70.55%IMAImageneBio75.00%MDCXMedicus PharmaN/APLURPluri16.59%Insider OwnershipCompanyInsider OwnershipERNAErnexa Therapeutics4.49%IMAImageneBio5.94%MDCXMedicus Pharma11.20%PLURPluri25.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERNAErnexa Therapeutics107.67 million7.33 millionNo DataIMAImageneBio704.02 million3.78 millionNot OptionableMDCXMedicus PharmaN/A17.82 million15.82 millionN/APLURPluri1507.87 million5.83 millionOptionableERNA, IMA, MDCX, and PLUR HeadlinesRecent News About These CompaniesPluri Resolves Nasdaq Compliance Issue with New DirectorSeptember 12, 2025 | tipranks.comPluri Appoints Eitan Ajchenbaum to Board of DirectorsSeptember 11, 2025 | tipranks.comPluri (PLUR) Projected to Post Earnings on WednesdaySeptember 10, 2025 | americanbankingnews.comPluri Inc. director not re-elected, Nasdaq compliance cure period grantedJuly 5, 2025 | investing.comInsider Buying: Pluri Inc. (NASDAQ:PLUR) Director Purchases 976,139 Shares of StockJuly 2, 2025 | insidertrades.comAlliance Global Partners Initiates Coverage of Pluri (PLUR) with Buy RecommendationJune 2, 2025 | msn.comPluri Inc. reschedules 2025 annual meetingMay 27, 2025 | investing.comBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsMay 27, 2025 | prnewswire.comBrainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plansMay 19, 2025 | msn.comPluri Inc.: Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.May 16, 2025 | finanznachrichten.dePluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market ExpansionMay 16, 2025 | tmcnet.comPluri: Fiscal Q3 Earnings SnapshotMay 13, 2025 | timesunion.comTPluri Inc. acquires majority stake in Kokomodo Ltd.April 30, 2025 | uk.investing.comPluri acquires 71% stake in KokomodoApril 29, 2025 | foodbusinessnews.netFPluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.April 28, 2025 | globenewswire.comPluri Inc. enters agreement, issues pre-funded warrantsApril 27, 2025 | investing.comUkraine gains access to Israeli anti-radiation drug amid nuclear threatsApril 21, 2025 | msn.comUkraine prepares for nuclear emergency - Israel to help save thousandsApril 21, 2025 | msn.comIn case of a nuclear event, Ukraine to use Israeli placenta-based emergency treatmentApril 20, 2025 | msn.comInnovative Treatment Aims to Protect Ukrainians from Nuclear Radiation ThreatApril 17, 2025 | themunicheye.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesChevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025How a Superstore Strategy Fueled MINISO’s 20% Stock SurgeBy Jeffrey Neal Johnson | August 26, 2025Lyft's Billion-Dollar Signal: Why Wall Street Is Betting BigBy Jeffrey Neal Johnson | August 19, 2025Advanced Micro Devices' 2026 Forecasts Are Way Too LowBy Thomas Hughes | September 5, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025ERNA, IMA, MDCX, and PLUR Company DescriptionsErnexa Therapeutics NASDAQ:ERNA$1.25 +0.07 (+5.51%) Closing price 04:00 PM EasternExtended Trading$1.30 +0.05 (+4.42%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.ImageneBio NASDAQ:IMA$8.52 -0.44 (-4.91%) As of 04:00 PM EasternImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.Medicus Pharma NASDAQ:MDCX$2.61 +0.13 (+5.24%) As of 04:00 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Pluri NASDAQ:PLUR$4.99 +0.09 (+1.73%) Closing price 03:57 PM EasternExtended Trading$4.81 -0.17 (-3.43%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
